Broad reactivity and enhanced potency of recombinant anti-EGFR × anti-CD3 bispecific antibody-armed activated T cells against solid tumours

Introduction: Bispecific antibody (BiAb)-armed activated T cells (BATs) comprise an adoptive T cell therapy platform for treating cancer. Arming activated T cells (ATC) with anti-CD3 x anti-tumour associated antigen (TAA) BiAbs converts ATC into non-major histocompatibility complex (MHC)-restricted...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Manley T. F., Sharma, Vikram, Mendelsohn, Andrew, Wei, Qisheng, Li, Jinjing, Yu, Bo, Larrick, James W., Lum, Lawrence G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045764/
https://www.ncbi.nlm.nih.gov/pubmed/36799362
http://dx.doi.org/10.1080/07853890.2022.2059101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045764/
https://www.ncbi.nlm.nih.gov/pubmed/36799362
http://dx.doi.org/10.1080/07853890.2022.2059101

Ejemplares similares